{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:07:29Z","timestamp":1785467249122,"version":"3.56.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12872-015-0001-9","type":"journal-article","created":{"date-parts":[[2015,2,25]],"date-time":"2015-02-25T06:09:47Z","timestamp":1424844587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population"],"prefix":"10.1186","volume":"15","author":[{"given":"Anping","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xida","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,26]]},"reference":[{"issue":"25 Suppl 2","key":"1_CR1","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff Jr DC, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino Sr RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49\u201373.","journal-title":"Circulation"},{"issue":"2","key":"1_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R Ross","year":"1999","unstructured":"Ross R. Atherosclerosis\u2013an inflammatory disease. N Engl J Med. 1999;340(2):115\u201326.","journal-title":"N Engl J Med"},{"issue":"10","key":"1_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.jacc.2005.02.058","volume":"45","author":"P Libby","year":"2005","unstructured":"Libby P. Act local, act global: inflammation and the multiplicity of \u201cvulnerable\u201d coronary plaques. J Am Coll Cardiol. 2005;45(10):1600\u20132.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1_CR4","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","volume":"27","author":"S Kiechl","year":"2007","unstructured":"Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27(8):1788\u201395.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"1_CR5","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM200003233421202","volume":"342","author":"PM Ridker","year":"2000","unstructured":"Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836\u201343.","journal-title":"N Engl J Med"},{"issue":"2","key":"1_CR6","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.coph.2005.11.008","volume":"6","author":"CH Macphee","year":"2006","unstructured":"Macphee CH, Nelson J, Zalewski A. Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2006;6(2):154\u201361.","journal-title":"Curr Opin Pharmacol"},{"issue":"9","key":"1_CR7","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jacc.2007.10.048","volume":"51","author":"LB Daniels","year":"2008","unstructured":"Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol. 2008;51(9):913\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1_CR8","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/01.ATV.0000240406.89440.0c","volume":"26","author":"Y Gerber","year":"2006","unstructured":"Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. downloaded. Arterioscler Thromb Vasc Biol. 2006;26(11):2517\u201322.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1_CR9","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/01.CIR.0000116763.91992.F1","volume":"109","author":"CM Ballantyne","year":"2004","unstructured":"Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837\u201342.","journal-title":"Circulation"},{"issue":"17","key":"1_CR10","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jacc.2007.11.079","volume":"51","author":"ER Mohler 3rd","year":"2008","unstructured":"Mohler 3rd ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51(17):1632\u201341.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.ahj.2011.01.017","volume":"161","author":"JS Berger","year":"2011","unstructured":"Berger JS, Ballantyne CM, Davidson MH, Johnson JL, Tarka EA, Lawrence D, et al. Peripheral artery disease, biomarkers, and darapladib. Am Heart J. 2011;161(5):972\u20138.","journal-title":"Am Heart J"},{"issue":"11","key":"1_CR12","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","volume":"118","author":"PW Serruys","year":"2008","unstructured":"Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118(11):1172\u201382.","journal-title":"Circulation"},{"issue":"10","key":"1_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/aps.2011.127","volume":"32","author":"MM Hu","year":"2011","unstructured":"Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin. 2011;32(10):1253\u20138.","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"1_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nm.1870","volume":"14","author":"RL Wilensky","year":"2008","unstructured":"Wilensky RL, Shi Y, Mohler 3rd ER, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14(10):1059\u201366.","journal-title":"Nat Med"},{"issue":"12A","key":"1_CR15","doi-asserted-by":"publisher","first-page":"51F","DOI":"10.1016\/j.amjcard.2008.04.019","volume":"101","author":"MH Davidson","year":"2008","unstructured":"Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol. 2008;101(12A):51F\u20137.","journal-title":"Am J Cardiol"},{"issue":"18","key":"1_CR16","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370(18):1702\u201311.","journal-title":"N Engl J Med"},{"issue":"10","key":"1_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML, Braunwald E, White HD, Steen DP, Lukas MA, Tarka E, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312(10):1006\u201315.","journal-title":"JAMA"},{"issue":"5","key":"1_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1155\/2013\/432136","volume":"34","author":"A Cai","year":"2013","unstructured":"Cai A, Zheng D, Qiu R, Mai W, Zhou Y. Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Dis Markers. 2013;34(5):323\u201331.","journal-title":"Dis Markers"},{"issue":"5","key":"1_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/MOL.0b013e3283307c16","volume":"20","author":"RL Wilensky","year":"2009","unstructured":"Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A(2) and atherosclerosis. Curr Opin Lipidol. 2009;20(5):415\u201320.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"1_CR20","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1253\/circj.CJ-12-0813","volume":"77","author":"H Daida","year":"2013","unstructured":"Daida H, Iwase T, Yagi S, Ando H, Nakajima H. Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe. Circ J. 2013;77(6):1518\u201325.","journal-title":"Circ J"},{"issue":"1","key":"1_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/01.ATV.0000191655.87296.ab","volume":"26","author":"EH Yang","year":"2006","unstructured":"Yang EH, McConnell JP, Lennon RJ, Barsness GW, Pumper G, Hartman SJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006;26(1):106\u201311.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"1_CR22","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1161\/CIRCULATIONAHA.106.671420","volume":"115","author":"S Lavi","year":"2007","unstructured":"Lavi S, McConnell JP, Rihal CS, Prasad A, Mathew V, Lerman LO, et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation. 2007;115(21):2715\u201321.","journal-title":"Circulation"},{"issue":"2","key":"1_CR23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.atherosclerosis.2007.02.012","volume":"196","author":"M Iwase","year":"2008","unstructured":"Iwase M, Sonoki K, Sasaki N, Ohdo S, Higuchi S, Hattori H, et al. Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment. Atherosclerosis. 2008;196(2):931\u20136.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1_CR24","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.atherosclerosis.2006.10.033","volume":"196","author":"AI Papathanasiou","year":"2008","unstructured":"Papathanasiou AI, Lourida ES, Tsironis LD, Goudevenos JA, Tselepis AD. Short- and long-term elevation of autoantibody titers against oxidized LDL in patients with acute coronary syndromes. Role of the lipoprotein-associated phospholipase A2 and the effect of atorvastatin treatment. Atherosclerosis. 2008;196(1):289\u201397.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1_CR25","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1161\/01.ATV.0000244681.72738.bc","volume":"26","author":"FD Kolodgie","year":"2006","unstructured":"Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12872-015-0001-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-015-0001-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-015-0001-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-015-0001-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T08:44:11Z","timestamp":1630572251000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-015-0001-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,26]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1"],"URL":"https:\/\/doi.org\/10.1186\/s12872-015-0001-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,26]]},"assertion":[{"value":"14 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}